NCT07531108CompletedPhase 4
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Serum Omentin 1 and Resistin in Treatment Naive Obese Patients With Type 2 Diabetes: A Clinical Prospective Study
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
This study compared the impacts of empagliflozin-metformin, sitagliptin-metformin, and metformin monotherapy in treatment-naive overweight or obese adults with newly diagnosed type 2 diabetes mellitus in Erbil, Iraq. The study monitored participants for 12 weeks. It determined changes in serum omentin-1, resistin, glycemic markers, and anthropometric measures.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 186 (actual)
- First submitted
- 6 Apr 2026
- Start date
- 15 Nov 2024
- Primary completion date
- 27 Nov 2025
- Lead sponsor
- Hawler Medical University
- Diseases
- Obesity, Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT07531108
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 186
- From 15 Nov 2024 to the primary completion date, 27 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of drugs known to affect adipokine levels, including glucocorticoids, statins, anti- inflammatory agents, hormonal therapies, or weight-loss medications.
Other illness
- Clinically significant cardiovascular, renal, or hepatic disease.
- Hypertension.
- Untreated or unstable thyroid disorders.
- Active psychiatric illness or use of psychotropic medications.
- Acute or ongoing infection.
Other
- Pregnancy or breastfeeding.
Who the study is looking for
- Adults aged 35 to 75 years.
- Newly diagnosed treatment-naive type 2 diabetes mellitus with no comorbidities
- HbA1c between 7% and 13%.
- Overweight or obese status, with BMI 25 to 45 kg/m².
- Waist circumference 94 to 130 cm for men or 80 to 130 cm for women.
- Waist-to-height ratio between 0.50 and 0.90.
- Willingness to provide written informed consent.
Age in the registry: 35 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Galyawa Teaching Center for Diabetes and Endocrinology Coordinator of this site? Confirm its status | Erbil | Iraq | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.